Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma

被引：0
|
作者：
Copley, Melissa [1 ]
Metheny, Leland [2 ]
Klisovic, Rebecca B. [1 ]
Malek, Ehsan [2 ]
机构：
[1] Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH USA
[2] Univ Hosp Seidman Canc Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Shaker Hts, OH USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162665
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13202 / 13203
页数：2
相关论文
共 50 条
  • [1] Subcutaneous versus intravenous daratumumab in multiple myeloma
    Shibusawa, Motoharu
    Tanimoto, Tetsuya
    [J]. LANCET HAEMATOLOGY, 2020, 7 (08): : E558 - E558
  • [2] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Yamaoka, Kenta
    Irie, Kei
    Hiramoto, Nobuhiro
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Hashida, Tohru
    Shimizu, Tadashi
    Ishikawa, Takayuki
    Muroi, Nobuyuki
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 761 - 767
  • [3] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Kenta Yamaoka
    Kei Irie
    Nobuhiro Hiramoto
    Masaki Hirabatake
    Hiroaki Ikesue
    Tohru Hashida
    Tadashi Shimizu
    Takayuki Ishikawa
    Nobuyuki Muroi
    [J]. Investigational New Drugs, 2023, 41 : 761 - 767
  • [4] Subcutaneous versus intravenous daratumumab in multiple myeloma reply
    Mateos, Maria-Victoria
    Usmani, Saad Z.
    [J]. LANCET HAEMATOLOGY, 2020, 7 (08): : E559 - E559
  • [5] Characteristics of Daratumumab Reactions in Patients Who Transitioned from Intravenous Daratumumab to Subcutaneous Daratumumab
    Kim, Chang Kun
    Douglass, Lindsey
    Gustafson, Beth
    Begemann, Madeline E.
    Cossor, Furha I.
    Gupta, Vinay
    Raza, Shahzad
    [J]. BLOOD, 2021, 138
  • [6] Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
    Sanchez, Larysa
    Richter, Joshua
    Cho, Hearn Jay
    Jagannath, Sundar
    Madduri, Deepu
    Parekh, Samir
    Richard, Shambavi
    Tam, Lowena
    Verina, Daniel
    Chari, Ajai
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [7] Daratumumab subcutaneous formulation for the treatment of multiple myeloma
    Paul, Barry
    Hamadeh, Issam
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Usmani, Saad Z.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (11) : 1253 - 1259
  • [8] Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
    Frerichs, Kristine A.
    Verkleij, Christie P. M.
    Dimopoulos, Meletios A.
    Marin Soto, Jhon A.
    Zweegman, Sonja
    Young, Mary H.
    Newhall, Kathryn J.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    [J]. CANCERS, 2021, 13 (10)
  • [9] An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
    Paul, Barry
    Atrash, Shebli
    Bhutani, Manisha
    Voorhees, Peter
    Hamadeh, Issam
    Usmani, Saad Z.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 795 - 802
  • [10] The safety of daratumumab for the treatment of multiple myeloma
    Cejalvo, Maria J.
    Ribas, Paz
    de la Rubia, Javier
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 753 - 760
12345